The Promise and Perils of Diversity Action Plans for Clinical Trials
JAMA · 03.12.2024 · 332 (21) · 1787
DOI: 10.1001/jama.2024.18225 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, erschienen am 03.12.2024. Verfasst von Tanvee Varma und 2 weiteren Autor:innen. Beteiligte Einrichtung: Brigham and Women's Hospital, Boston, Massachusetts. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
This Viewpoint discusses the US Food and Drug Administration’s authority to require drug and device sponsors to submit diversity action plans and policy gaps that limit the organization’s ability to achieve demographic representation in clinical trials.
Autor:innen und Institutionen
- Brigham and Women's Hospital, Boston, Massachusetts.
- Harvard Medical School, Boston, Massachusetts.
- Dana-Farber Cancer Institute, Boston, Massachusetts.
Förderung
- NCI NIH HHS
Zitieren
APA
Varma, T., Bierer, B. E., & Hantel, A. (2024). The Promise and Perils of Diversity Action Plans for Clinical Trials. JAMA, 332(21), 1787. https://doi.org/10.1001/jama.2024.18225
Vancouver
Varma T, Bierer BE, Hantel A. The Promise and Perils of Diversity Action Plans for Clinical Trials. JAMA. 2024;332(21):1787. doi:10.1001/jama.2024.18225
BibTeX
@article{Varma2024,
author = {Varma, Tanvee and Bierer, Barbara E and Hantel, Andrew},
title = {The Promise and Perils of Diversity Action Plans for Clinical Trials},
journal = {JAMA},
year = {2024},
volume = {332},
number = {21},
pages = {1787},
doi = {10.1001/jama.2024.18225}
}
EUVIMED